JAKPot for treating bone loss
Researchers report that JAK inhibitors a class of approved anti-inflammatory drugs prevented bone loss in mice with osteoporosis and two patients with rheumatoid arthritis.
Mereo BioPharma raise money to back Phase III trials
Mereo BioPharma has entered into a $5m convertible equity financing with Novartis and a $28m securities purchase agreement with Aspire Capital Fund.
BIH scientists optimise CRISPR gene scissors
Targeted genome editing using the CRISPR-Cas9 system is easy to use but far from being perfect. Computer calculated modification of CRISPR activity can reduce "off-target effects".
Azafaros BV raises 25m in Series A round
Dutch biotech Azafaros B.V. has closed a 25m Series A financing round.
Researchers identify roots of childhood asthma
Infants who show defective immune responses to microbial components are more likely to acquire asthma later in childhood, according to a study of 541 children.
MaaT Pharma raise 18m to advance clinical pipeline
MaaT Pharma SA has announced 18m Series B financing to boost its microbiome biotherapeutics pipeline.
Stilla raises 20m in series B financing round
French Stilla Technologies SA raised 20m in a Series B funding to boost digital PCR-based genetic testing.
Valneva raises US$85m
French vaccine developer Valneva SA will raise $85m in a financing arrangement with Deerfield and OrbiMed and go Nasdaq to co-fund its Lyme disease programme.
Sleeping sickness target deciphered
Researchers at the University of Luebeck have revealed the structure of the IMP dehydrogenase, a central target of T. brucei, which causes sleeping sickness.